Therapeutic Response
CD20 +
status confers therapeutic sensitivity to
Cyclophosphamide
in combination with
Fludarabine,
Mitoxantrone, and
Rituximab
in patients with
Non-Hodgkin Lymphoma.
Statements
| Source and description |
Rituxan (rituximab) [package insert]. FDA.
The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).
|